Taprizosin

• Description :

  Taprizosin (UK-338003) is an α-adrenoreceptor antagonist[1].

• CAS Number :

  [210538-44-6]

• Product Name Alternative :

  UK-338003

• UNSPSC :

  12352005

• Target :

  Adrenergic Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Cardiovascular Disease; Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/taprizosin.html

• Smiles :

  CS(=O)(NC1=CC=CC2=C1CCN(C3=NC(N)=C4C(C5=NC=CC=C5)=C(OC)C(OC)=CC4=N3)C2)=O

• Molecular Formula :

  C25H26N6O4S

• Molecular Weight :

  506.58

• References & Citations :

  [1]Collett A, et al. Investigation of regional mechanisms responsible for poor oral absorption in humans of a modified release preparation of the alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2- (5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl) -5- (2-pyridyl) quinazoline (UK-338,003) : the rational use of ex vivo intestine to predict in vivo absorption. Drug Metab Dispos. 2008 Jan;36 (1) :87-94.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2